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epressive disorders constitute a major public
health issue,and are estimated to rank in second position
among all diseases by the year 2010, thus contributing
heavily to the global burden of diseases in man,accord-
ing to Murray and Lopez,who conducted a study for the
World Health Organization (WHO).
1 Therefore, the
effort to alleviate depressive symptoms in the general
population is a major public health issue.The concept of
clinical remission in the treatment of major depressive
disorders has gained growing attention in the last few
years.The reasons for this relatively recent interest are
manifold.Depressed patients,as well as patient organi-
zations,are not totally satisfied with the current effective-
ness and tolerance of available antidepressant medica-
tions. Despite the obvious benefits of antidepressants,
many depressed patients are still suffering from incapac-
itating residual symptoms.Furthermore,follow-up inves-
tigations have demonstrated that depressed patients who
do not reach full remission after antidepressant therapy,
that is, patients who are still presenting a number of
residual symptoms, are at a higher risk of relapse or
recurrence than patients achieving full remission after
treatment.
2-4 Conversely,depressed patients who reach
full remission after treatment have a better level of func-
tioning
5 and have an improved prognosis
6 compared with
patients who are nonremitters.
Adequate clinical remission is therefore of great func-
tional importance for the patient,because it seems to be
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The burden of depressive illness constitutes a major pub-
lic health issue. Despite real progress and better tolerance
of new antidepressant medications, a significant number
of depressed patients still suffer from rather severe resid-
ual depressive symptoms.This relative lack of efficacy
clearly interferes with their psychosocial functioning and
their quality of life. In addition, it is now well-recognized
that the failure to reach full clinical remission after anti-
depressant treatment involves a high risk of relapse or
recurrence in patients suffering from major depression.
This paper reviews the concept of remission across differ-
ent definitions, and the potential risk factors associated
with the failure to reach clinical remission. The identifica-
tion of specific residual symptoms in nonremitted patients
is also of great importance, in order to assess the predic-
tive value of those symptoms in relation to relapse and
recurrence. Some methodological issues are also discussed,
as well as various therapeutic strategies aimed at reliev-
ing residual depressive symptoms. Clinical remission
remains a gold standard and a primary objective of mod-
ern antidepressant therapy.
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:371-375.a predictor of long-term stability and a rather good indi-
cator of better psychosocial functioning, which is of
utmost importance for assessing quality of life in our
depressed patients.
7-9 For the above reasons,it becomes
of great interest to the scientific community and to our
patients to report,in future clinical trials,not only rates
of responders but also remission rates,in order to assess
the real clinical efficacy of antidepressants and to posi-
tion new treatments in outcome studies.
Definitions of remission may vary across the literature,and
questions arise about the boundaries between full remis-
sion and partial remission,the presence after treatment of
residual symptoms, and the return or not to premorbid
psychosocial functioning.During a consensus conference
supported by the MacArthur Foundation,Frank and col-
leagues
10 came up with a number of operational definitions
to assess the complex course of depressive disorders.
Partial remission is defined as a period of time with some
improvement of symptoms,but not of enough magnitude
as to achieve full remission, and with the persistence of
some residual symptoms.This state corresponds to a score
of 8 to 15 on the Hamilton Rating Scale for Depression
(HAM-D17).Conversely,full remission is obtained where
clinical improvement is such that the patient becomes
almost asymptomatic.Clinical remission is usually defined
by a score of 7 or less on the HAM-D17 or a score of 10-
12 or less on the Montgomery Åsberg Depression Rating
Scale (MADRS).
Zimmerman and Colleagues
11 have analyzed the impli-
cations of using various cutoff scores on symptom sever-
ity scales in order to define clinical remission in
depressed patients as part of the Rhode Island Method
to Improve Diagnostic Assessments and Services
(MIDAS) project. They also assessed the association
between remission status and psychosocial impairments
for different cutoff scores for remission in 303 depressed
outpatients using the MADRS,the HAM-D17,and an
index of the DSM-IV remission status.For both severity
scales,the different levels of cutoff scores were associated
with different rates of remission.The high cutoff scores
were also associated with higher rates of psychosocial
impairment.
These results may suggest that the lower the cutoff scores
used to define remission,the more valid the results may
be in term of clinical relevance and quality of life assess-
ment after antidepressant therapy.
A valuable approach of interest to practising psychiatrists
has been proposed by McIntyre and Colleagues,
12 who
have designed a shorter version of the HAM-D17 using
7 items out of the 17 items of the original scale,based on
frequency and sensitivity to changes after antidepressant
treatment.The authors then attempted to validate this
shortened questionnaire,called the Toronto HAM-D7,
in a sample of 292 patients with major depression fol-
lowed up in a depression clinic in Toronto.
The results indicate that a score of three or less on the
Toronto HAM-D7 did correlate with the score of seven
or less for remission on the 17 items of the HAM-D17.
If this is confirmed in additional validation studies, the
Toronto HAM-D7 Scale could be of practical use for
general practitioners and for psychiatrists,as well as for
use as a screening tool to be used in some antidepres-
sant trials.An American College of Neuropsychophar-
macology (ACNP) Task Force reached consensus guide-
lines after conducting a critical review of the literature
and exchanging expert clinical experience.The ACNP
Task Force then made several recommendations,which
are,however,generally not evidence-based,on the con-
cept of remission in major depressive disorders.
6 Table
I summarizes some of the ACNP Task Force recommen-
dations.
The ACNP Task Force also reviewed the literature on
potential associated factors which may influence the
remission,the time of remission and the stability of the
remission.
6These factors include among others the type
of treatment,the dose,the duration of treatment,base-
line severity of depressive symptoms,the stage of treat-
ment resistance (TRD),the compliance,the presence of
DSM-IV Axis I,II,or III conditions,environmental stres-
sors,the degree of social support,and the retrospective
morbidity of the illness,as well as neurobiological and
genetic vulnerability.
There is no general consensus about the length of time
the depressed patient in remission should remain in
remission,but,according to most experts,this period of
remission is expected to last between 4 and 6 months to
be of clinical relevance for the patient.
10
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Selected abbreviations and acronyms
HAM - D17 Hamilton Rating Scale for Depression – 
17 items
HAMD-D7 Toronto Hamilton Rating Scale for
Depression – 7 items
MADRS Montgomery Åsberg Depression Rating Scale
MIDAS Rhode Island Method to Improve
Assessments and ServicesThe length of the remission period is obviously of great
clinical relevance to the patient,and is also contingent on
the continuation of antidepressant treatment.In a review
of 31 randomized trials,Geddes and Colleagues
13 have
shown that continuing treatment with antidepressants
reduced the risk of relapse by 70% compared with treat-
ment discontinuation.The treatment effect seemed to
persist for between 12 and 36 months.
A long-term naturalistic study conducted in Japan by
Furukawa and Colleagues in a cohort of 95 unipolar
major depressive patients followed up for a 10-year
period was recently reported.
14The authors assessed the
definition of recovery according to the length of time of
remission. Based on the results, they concluded that a
period of 2 months of remission was too short to define
recovery,but proposed that a period of 4 to 6 months of
remission may be more adequate.This study,however,
was not controlled and the sample size was too small to
draw definitive conclusions.
Unfortunately,as previously stated,a significant number
of patients do not remain symptom-free and continue to
present subsyndromal depression or subthreshold
depression for some time during their lifetime. These
patients have been shown to have a higher risk of early
relapse into depression,lower levels of social and psycho-
logical functioning,and greater rates of physical morbid-
ity such as cardiovascular disease and stroke,as well as
higher rates of mortality.
15Thase has reported that more
than one third of depressed patients will reach remission
after acute antidepressant treatment.
16 Most clinical tri-
als report remission rates of 22% to 40%,
17 while effec-
tiveness studies including representative samples of
depressed patients closer to clinical practice report lower
remission rates—around 11% to 30%.
18-21The identifica-
tion of predicting factors of nonremission (the persis-
tence of residual symptoms) in antidepressant therapy
has not been conclusive for such factors as personality
traits,the impact of life events,and even baseline sever-
ity level of depression.
15 Some authors, such as
Zimmerman et al,
22 have proposed that the concept of
remission not be restricted to scores of symptoms on
severity scales like the HAM-17 or MADRS,but that the
definition of remission be enlarged to the restoration of
normal functioning and the improvement of quality of
life.This conclusion was reached based on the results of
the MIDAS project, in which 514 depressed patients
were asked for their subjective evaluation of their remis-
sion status in relation to the severity levels of their
depressive illness and their degree of functional impair-
ment.
These variables were found to be correlated and also 
predictive of their remission state. McGlinchey and
Colleagues
23 have evaluated factors such as gender,age,
and depressed state on patient’s perspectives of remis-
sion. They were able to complete a survey in 560
depressed outpatients using The Standardized Clinical
Outcome Rating Scale for Depression (SCOR-D) an
instrument including DSM-IV criteria for major depres-
sive episodes and for psychosocial impairment. The
results showed that the perspective on remission was dif-
ferent in men compared with women,as well as in older
versus younger depressed patients. Female depressed
patients related the perception of remission more to
emotional stability,and older depressed patients empha-
sized more the necessity to reach a state of well-being.
Several therapeutic strategies have been proposed to
achieve remission
16 or to treat residual symptoms in
patients suffering major depressive disorders.
24Among
the most frequent residual symptoms targeted,one finds
anxiety symptoms,sleep disturbances,depressed mood,
work difficulties,fatigue,and lack of interest.
15,24,25
The rather high rate of manifestation of residual symp-
toms observed in nonremitted depressed patients justifies
the need for research into various therapeutic strategies
such as switching,augmentation,combination therapies,
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Remission
• A primary end point in acute antidepressant treatment
• Is present if equal or more than 3 weeks 
• Day-to-day function is secondary outcome
• Trials using remission as primary outcome must last longer 
(12-20 weeks)
Relapse
• Occurs following remission and before recovery
• Requires a DSM-IV diagnostic criteria for Major Depressive 
Episode (MDE) to be met
Recovery
• Can only be defined after more than 4 months following the 
onset of remission
Recurrence
• Occurrence of MDE defined by DSM-IV
• Occurs after the onset of recovery
Table I. Summary of ACNP Task Force recommendations.
Adapted from ref 6: Rush AJ, Kraemer HC, Sackeim HA, et al. Report by
the ACNP Task Force on Response and Remission in Major Depressive
Disorder. Neuropsychopharmacology. 2006;31:1841-1853. Copyright ©
Nature Publishing Group 2006including with cognitive behavioral therapy,and the search
for new targets to develop novel and more efficacious anti-
depressant treatments.This strategy has been applied in
the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) Study
26 which has a rather com-
plex and problematic design and which examines,among
several issues,the rates of remission and time to remission
after an initial treatment with a selective serotonin reup-
take inhibitor,in this case citalopram,and after subsequent
treatment steps, including switching to bupropion sus-
tained-release, cognitive behavioral therapy, sertraline,
venlafaxine extended-release,or augmentation of citalo-
pram with bupropion sustained-release,buspirone,or cog-
nitive therapy.
Remission rate after the first step was about 30%, and
jumped to 50% after the second phase of treatment,but
did not improve after subsequent treatments.An impor-
tant observation from the STAR*D Study was that a
large number of patients in each treatment group did
not actually reach remission after 6 to 8 weeks of treat-
ment.Thus, the remission state may indeed take more
time to achieve in comparison with a simple response in
antidepressant trials. Thus, future trials designed to
assess remission as the primary end point in acute treat-
ment studies should probably last at least 8 weeks, and
maybe more.
Conclusion
There is general consensus to consider remission after
acute antidepressant treatment as the gold standard and
main objective of modern antidepressant therapy,but,
before the dream becomes reality for the great majority
of our depressed patients,innovative strategies and novel
etiology-based therapeutic approaches will have to be
explored in rigorous controlled investigations combining
creative clinical expertise and innovative biomarker
research. ❏
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La obtención de la remisión como objetivo
de la terapia de la depresión 
La carga de la enfermedad depresiva constituye un
tema muy importante de salud pública. A pesar del
progreso real y de la mejor tolerabilidad de los nue-
vos medicamentos antidepresivos, un número sig-
nificativo de pacientes con depresión todavía sufre
de bastantes síntomas depresivos residuales graves.
Esta relativa falta de eficacia claramente interfiere
con su funcionamiento psicosocial y su calidad de
vida. Además, actualmente está bien reconocido
que el fracaso en la obtención de la remisión clínica
completa después del tratamiento antidepresivo
involucra un alto riesgo de recaídas o recurrencias
en pacientes que padecen de depresión mayor. Este
artículo revisa el concepto de remisión a través de
diferentes definiciones, y los potenciales factores de
riesgo asociados con el fracaso en la obtención de
la remisión clínica. También es de gran importancia
la identificación de síntomas residuales específicos
en pacientes que no remiten, para evaluar el valor
predictor de dichos síntomas en relación con reca-
ídas y recurrencias. Asimismo se discuten algunos
temas metodológicos, al igual que varias estrate-
gias terapéuticas orientadas al alivio de los sínto-
mas depresivos residuales. La remisión clínica per-
siste como el gold standard y es un objetivo
primordial de la moderna terapia antidepresiva.  
Vers la rémission dans le traitement de la
dépression
Le fardeau de la maladie dépressive est un pro-
blème majeur de santé publique. Malgré les pro-
grès réels et la meilleure tolérance des nouveaux
antidépresseurs, un nombre significatif de patients
déprimés se plaignent encore de symptômes
dépressifs résiduels sévères. Ce manque relatif d’ef-
ficacité interfère nettement avec leur fonctionne-
ment psychosocial et leur qualité de vie. Le risque
élevé de rechute ou de récidive après un traitement
antidépresseur n’ayant pas permis une rémission cli-
nique complète chez des patients souffrant de
dépression majeure, est maintenant bien reconnu.
Cet article analyse le concept de rémission à travers
différentes définitions ainsi que les facteurs poten-
tiels de risque associés à son échec. Identifier les
symptômes résiduels spécifiques chez des patients
sans rémission est aussi très important afin d’éva-
luer leur valeur prédictive dans la rechute et la réci-
dive. Certaines questions méthodologiques sont
traitées, comme les différentes stratégies thérapeu-
tiques visant à soulager les symptômes dépressifs
résiduels. La rémission clinique est un critère de
référence et le premier objectif d’un traitement
antidépresseur moderne.